K8 was found to reduce geographic atrophy lesion area growth by more than 50% in its first human clinical trial of the drug.

The company plans to raise money this fall to support the continued development of its head-and-neck cancer testing platform and oral squamous cell carcinoma test.

For more than 60 years, the medical community has been refining the diagnosis of multiple sclerosis. The diagnosis of multiple sclerosis typically involves the detection of demyelinating episodes that ...